Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
Anavex (Nasdaq: AVXL) announced an oral presentation delivered by Prof. Dr. Timo Grimmer, MD, member of the company's Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX®2-73-AD-004 study, at the 35th Alzheimer Europe Conference on October 10, 2025.
The presentation, titled “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine,” is available on Anavex’s investors website.
This release discusses investigational uses of an agent in development and does not draw conclusions about efficacy or safety; there is no guarantee the investigational product will complete clinical development or obtain health authority approval.
Anavex (Nasdaq: AVXL) ha annunciato una presentazione orale tenuta da Prof. Dr. Timo Grimmer, MD, membro del Scientific Advisory Board dell'azienda e Investigatore Coordinatore Nazionale per lo studio di blarcamesine Phase IIb/III ANAVEX®2-73-AD-004, al 35ª Conferenza Alzheimer Europe il 10 ottobre 2025.
La presentazione, intitolata “Avanzando la cura della malattia di Alzheimer: comodità sia per i pazienti che per le famiglie con la blarcamesina orale,” è disponibile sul sito per investitori di Anavex.
Questo comunicato discute usi sperimentali di un agente in sviluppo e non trae conclusioni sull'efficacia o sulla sicurezza; non c'è alcuna garanzia che il prodotto sperimentale completi lo sviluppo clinico o ottenga l'approvazione delle autorità sanitarie.
Anavex (Nasdaq: AVXL) anunció una presentación oral realizada por el Prof. Dr. Timo Grimmer, MD, miembro de la Junta Asesora Científica de la empresa y Investigador Coordinador Nacional para el estudio de blarcamesina Phase IIb/III ANAVEX®2-73-AD-004, en la 35th Alzheimer Europe Conference el 10 de octubre de 2025.
La presentación, titulada “Avanzando la atención de la enfermedad de Alzheimer: conveniencia tanto para pacientes como para las familias con blarcamesina oral,” está disponible en el sitio web de inversores de Anavex.
Este comunicado discute usos de un agente en desarrollo y no extrae conclusiones sobre eficacia o seguridad; no hay garantía de que el producto experimental complete el desarrollo clínico u obtenga la aprobación de las autoridades sanitarias.
Anavex (Nasdaq: AVXL)는 회사의 과학 자문 위원회(SAB) 구성원이며 blarcamesine 2상-3상 ANAVEX®2-73-AD-004 연구의 국가 조정 연구책임자인 Prof. Dr. Timo Grimmer, MD가 발표한 구두 발표를 제35회 Alzheimer Europe Conference에서 2025년 10월 10일에 발표했다고 발표했습니다.
발표 제목은 “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine”이며 Anavex의 투자자 웹사이트에서 볼 수 있습니다.
이 발표 자료는 개발 중인 제원의 임상적 사용에 대해 논의하며 효능이나 안전성에 대한 결론을 도출하지 않으며, 임상 개발을 완료하거나 보건당국의 승인을 받을 보장은 없습니다.
Anavex (Nasdaq: AVXL) a annoncé une présentation orale réalisée par Prof. Dr. Timo Grimmer, MD, membre du Scientific Advisory Board de l'entreprise et Investigateur Coordonnateur National pour l'étude sur la blarcamesine Phase IIb/III ANAVEX®2-73-AD-004, lors de la 35e conférence Alzheimer Europe le 10 octobre 2025.
La présentation, intitulée “Avancer dans les soins de la maladie d’Alzheimer : commodité pour les patients et les familles avec la blarcamesine orale,” est disponible sur le site des investisseurs d’Anavex.
Ce communiqué discute des usages investigatoires d’un agent en développement et ne tire pas de conclusions sur l’efficacité ou la sécurité; il n’y a aucune garantie que le produit expérimental finalise le développement clinique ou obtienne l’approbation des autorités sanitaires.
Anavex (Nasdaq: AVXL) kündigte eine mündliche Präsentation von Prof. Dr. Timo Grimmer, MD, Mitglied des Scientific Advisory Board des Unternehmens und National Coordinating Investigator für die Blarcamesine-Studie ANAVEX®2-73-AD-004 Phase IIb/III, bei der 35. Alzheimer Europe Conference am 10. Oktober 2025 an.
Die Präsentation mit dem Titel “Fortschritt in der Alzheimer-Behandlung: Komfort für Patienten und Familien mit oraler Blarcamesine” ist auf der Investorenseite von Anavex verfügbar.
Diese Veröffentlichung behandelt erkundungsbezogene Anwendungen eines in Entwicklung befindlichen Mittels und zieht keine Schlussfolgerungen zu Wirksamkeit oder Sicherheit; es gibt keine Garantie, dass das Prüfpräparat die klinische Entwicklung abschließt oder die Zulassung durch Gesundheitsbehörden erhält.
أنافِكس (ناسداك: AVXL) أعلنت عن عرض شفهي قدمه الأستاذ الدكتور تيمو غريمِر، طبيب، عضو مجلس المستشارين العلمي للشركة وInvestigador Coordinating الوطني للدراسة بلاركيمسينا المرحلة IIb/III ANAVEX®2-73-AD-004، في المؤتمر 35th Alzheimer Europe Conference في 10 أكتوبر 2025.
العرض، بعنوان “تقدم رعاية مرض الزهايمر: راحة لكل من المرضى والعائلات مع بلاركيمسين الفموي,” متاح على موقع المستثمرين الخاص بـ Anavex.
يناقش هذا البيان استخدامات استقصائية لعامل في طور التطوير ولا يستخلص استنتاجات حول الفعالية أو السلامة؛ لا توجد ضمانة بأن يكمل المنتج التجريبي التطوير السريري أو يحصل على موافقة السلطات الصحية.
Anavex (Nasdaq: AVXL) 宣布一场口头报告，由 Prof. Dr. Timo Grimmer, MD（公司科学顾问委员会成员，blarcamesine 的阶段 IIb/III ANAVEX®2-73-AD-004 研究的国家协调研究负责人）在 第35届 Alzheimer Europe Conference 于 2025年10月10日 进行。
题为“推进阿尔茨海默病护理：口服 blarcamesine 给患者和家庭带来的便利”的报告，可在 Anavex 投资者网站查看。
本新闻稿讨论在研药物的探索性用途，不对疗效或安全性作出结论；不能保证该研究药物会完成临床开发或获得卫生监管机构批准。
- None.
- None.
Presentation title: “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine”
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Prof. Dr. Timo Grimmer, MD, member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX®2-73-AD-004 study gave an oral presentation titled, “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’.
The presentation is available on the Investors section of the Company’s website at www.anavex.com.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
What did Anavex (AVXL) present at the 35th Alzheimer Europe Conference on October 10, 2025?
Who is Prof. Dr. Timo Grimmer in relation to Anavex (AVXL)?
Where can investors watch the Anavex (AVXL) conference presentation from October 10, 2025?
Does the Anavex (AVXL) release claim blarcamesine is safe and effective?
Which clinical study of blarcamesine was referenced in the Anavex (AVXL) presentation?
